This clinical trial is focused on studying the treatment of Rheumatoid Arthritis, a chronic inflammatory disorder that primarily affects the joints. The study involves the use of a medication called Rituximab, which is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein. The trial will compare two different strategies for adjusting the dosage of Rituximab in patients who have previously responded to this treatment. The goal is to find the best way to reduce the impact of the disease while maintaining effective control over its symptoms.
Participants in the study will receive Rituximab over a period of 104 weeks, which is approximately two years. During this time, the study will explore two approaches: one that involves extending the time between doses and another that adjusts the dose based on the patient’s disease activity. The trial aims to determine which method is more effective in managing Rheumatoid Arthritis and reducing the overall amount of medication needed.
The study will also monitor various aspects of the disease and treatment, such as the overall impact on the patient’s health, the activity level of the disease, and any side effects that may occur. By comparing these factors, the trial seeks to provide valuable insights into optimizing Rituximab treatment for individuals with Rheumatoid Arthritis.
Belgium 
